Sulfatinib

Drug Profile

Sulfatinib

Alternative Names: HMPL-012; Sufatinib; Suofantini

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuroendocrine tumours
  • Phase II Biliary cancer; Thyroid cancer
  • Phase I Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 10 Mar 2017 Efficacy and safety data from a phase Ib/II trial n endocrine tumours released by Hutchison MediPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top